CoDx - קצב צמיחת הכנסות משנה לשנה ב-12 החודשים האחרונים CODX

Co-Diagnostics, Inc. (CODX) designs its DNA platforms in-house while outsourcing cartridge production to external partners. The year-over-year revenue change over the last 12 months reflects business dynamics where the current status is 28.60. Stability is maintained through strict control of reagent supply chains. High barriers to entry, created by CoPrime system patents and costly laboratory certifications, protect the company from new entrants.
codiagnostics.com (CODX) - פילוחי מדדים ודוחות פיננסיים

Co-Diagnostics, Inc. (CODX) is currently transforming its molecular test portfolio, shifting from pandemic-related products toward infection diagnostics and the agricultural sector. By analyzing the TTM annual revenue growth chart, one can assess the effectiveness of this product line update. This metric compares current revenue over the last 12 months with the same period last year, neutralizing seasonality. The smoothed trend reveals real demand dynamics stripped of market noise. It is critical for investors to weigh this growth against the development costs of new systems.